RTGN
RetinalGenix Technologies Inc.
Price Chart
Latest Quote
$4.00
| Previous Close | $4.00 |
| Open | $4.00 |
| Day High | $4.00 |
| Day Low | $4.00 |
| Volume | 19 |
Stock Information
| Shares Outstanding | 18.84M |
| Total Debt | $55K |
| Cash Equivalents | $180 |
| Net Income | $-2.43M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $75.37M |
| EPS (TTM) | $-0.13 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $75.43M |
| Income | $-2.43M |
| Book/sh | $-0.14 |
| Cash/sh | $0.00 |
Financial Ratios
Returns & Margins
| ROA | -17108.35% |
Ownership
| Insider Ownership | 65.30% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -29.41 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $4.00 |
| SMA50 | $3.68 |
| SMA200 | $3.41 |
| RSI | nan |
| Shares Float | 6.27M |
| Volatility | -3.36 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +25.00% |
| 6 Months | +25.00% |
| YTD | +25.00% |
| Year | -20.32% |
| 3 Years | -55.56% |
| 10 Years | +33.33% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-15 | $4.00 | 0 |
| 2026-06-12 | $4.00 | 0 |
| 2026-06-11 | $4.00 | 0 |
| 2026-06-10 | $4.00 | 0 |
| 2026-06-09 | $4.00 | 0 |
| 2026-06-08 | $4.00 | 0 |
| 2026-06-05 | $4.00 | 0 |
| 2026-06-04 | $4.00 | 0 |
| 2026-06-03 | $4.00 | 0 |
| 2026-06-02 | $4.00 | 0 |
| 2026-06-01 | $4.00 | 0 |
| 2026-05-29 | $4.00 | 0 |
| 2026-05-28 | $4.00 | 0 |
| 2026-05-27 | $4.00 | 0 |
| 2026-05-26 | $4.00 | 0 |
| 2026-05-22 | $4.00 | 0 |
| 2026-05-21 | $4.00 | 0 |
| 2026-05-20 | $4.00 | 0 |
| 2026-05-19 | $4.00 | 0 |
| 2026-05-18 | $4.00 | 0 |
About RetinalGenix Technologies Inc.
RetinalGeniX Technologies Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders. The company offers the Retinal Imaging Screening Device, a portable retinal imaging system providing a wide field of view without requiring pupil dilation; and RetinalCam, an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians. It also develops RTG-2023 for the treatment of dry age-related macular degeneration; and RTG-2024 for the treatment of Alzheimer's syndrome dementia. The company was incorporated in 2017 and is based in Apollo Beach, Florida. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
đ° Latest News
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $703,930 | $403,658 | $370,523 | $361,580 |
| Cost Of Revenue | $703,930 | $403,658 | $370,523 | $361,580 |
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $3,840 | $3,840 | $5,140 | $2,619 |
| Total Expenses | $4,316,987 | $2,087,049 | $1,875,961 | $2,176,675 |
| Net Non Operating Interest Income Expense | $-3,840 | $-3,840 | $-5,140 | $-2,619 |
| Interest Expense Non Operating | $3,840 | $3,840 | $5,140 | $2,619 |
| Operating Expense | $3,613,057 | $1,683,391 | $1,505,438 | $1,815,095 |
| General And Administrative Expense | $3,239,786 | $1,159,208 | $696,183 | $1,067,287 |
| Other Income Expense | - | - | $-2,032,889 | $-680,293 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,320,827 | $-2,090,889 | $-3,913,990 | $-2,179,294 |
| Net Interest Income | $-3,840 | $-3,840 | $-5,140 | $-2,619 |
| Normalized Income | $-4,320,827 | $-2,090,889 | $-1,881,101 | $-2,179,294 |
| Net Income From Continuing And Discontinued Operation | $-4,320,827 | $-2,090,889 | $-3,913,990 | $-2,179,294 |
| Net Income Common Stockholders | $-4,320,827 | $-2,090,889 | $-3,913,990 | $-2,179,294 |
| Net Income | $-4,320,827 | $-2,090,889 | $-3,913,990 | $-2,179,294 |
| Net Income Including Noncontrolling Interests | $-4,320,827 | $-2,090,889 | $-3,913,990 | $-2,179,294 |
| Net Income Continuous Operations | $-4,320,827 | $-2,090,889 | $-3,913,990 | $-2,179,294 |
| Pretax Income | $-4,320,827 | $-2,090,889 | $-3,913,990 | $-2,179,294 |
| Operating Income | $-4,316,987 | $-2,087,049 | $-1,875,961 | $-2,176,675 |
| Gross Profit | $-703,930 | $-403,658 | $-370,523 | $-361,580 |
| Special Income Charges | - | $0 | $-2,032,889 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.24 | $-0.12 | $-0.25 | $-0.15 |
| Basic EPS | $-0.24 | $-0.12 | $-0.25 | $-0.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-4,316,033 | $-2,086,949 | $-1,875,910 | $-2,176,675 |
| Reconciled Depreciation | $954 | $100 | $51 | $0 |
| EBITDA (Bullshit earnings) | $-4,316,033 | $-2,086,949 | $-3,908,799 | $-2,176,675 |
| EBIT | $-4,316,987 | $-2,087,049 | $-3,908,850 | $-2,176,675 |
| Diluted Average Shares | $17,940,639 | $17,352,196 | $15,584,346 | $14,282,314 |
| Basic Average Shares | $17,940,639 | $17,352,196 | $15,584,346 | $14,282,314 |
| Diluted NI Availto Com Stockholders | $-4,320,827 | $-2,090,889 | $-3,913,990 | $-2,179,294 |
| Research And Development | $373,271 | $524,183 | $809,255 | $747,808 |
| Selling General And Administration | $3,239,786 | $1,159,208 | $696,183 | $1,067,287 |
| Other Gand A | $630,000 | $495,000 | $436,883 | $759,369 |
| Salaries And Wages | $2,609,786 | $664,208 | $259,300 | $307,918 |
| Total Unusual Items | - | $0 | $-2,032,889 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-2,032,889 | $0 |
| Other Special Charges | - | - | $2,032,889 | $680,293 |
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,462,610 | $-1,405,657 | $-1,069,063 | $-464,675 |
| Total Assets | $14,946 | $156 | $294 | $4,947 |
| Total Non Current Assets | $8,886 | $156 | $256 | $0 |
| Non Current Prepaid Assets | $1,995 | $0 | - | - |
| Current Assets | $6,060 | $0 | $38 | $4,947 |
| Cash Cash Equivalents And Short Term Investments | $6,060 | $0 | $38 | $4,947 |
| Cash And Cash Equivalents | $6,060 | $0 | $38 | $4,947 |
| Cash Financial | $6,060 | $0 | $38 | $4,947 |
| Current Deferred Assets | - | - | - | $0 |
| Receivables | - | - | - | $0 |
| Debt | ||||
| Net Debt | $42,940 | $49,000 | $48,962 | $68,053 |
| Total Debt | $56,532 | $49,000 | $49,000 | $73,000 |
| Long Term Debt And Capital Lease Obligation | $6,544 | $0 | - | - |
| Current Debt And Capital Lease Obligation | $49,988 | $49,000 | $49,000 | $73,000 |
| Current Debt | $49,000 | $49,000 | $49,000 | $73,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $1,477,556 | $1,405,813 | $1,069,357 | $469,622 |
| Total Non Current Liabilities Net Minority Interest | $6,544 | $0 | $0 | $0 |
| Current Liabilities | $1,471,012 | $1,405,813 | $1,069,357 | $469,622 |
| Current Notes Payable | $49,000 | $49,000 | $49,000 | $73,000 |
| Payables And Accrued Expenses | $1,421,024 | $1,356,813 | $1,020,357 | $396,622 |
| Interest Payable | $15,439 | $11,599 | $7,759 | $2,619 |
| Payables | $1,405,585 | $1,345,214 | $1,012,598 | $394,003 |
| Accounts Payable | $922,083 | $884,920 | $475,480 | $251,282 |
| Equity | ||||
| Common Stock Equity | $-1,462,610 | $-1,405,657 | $-1,069,063 | $-464,675 |
| Total Equity Gross Minority Interest | $-1,462,610 | $-1,405,657 | $-1,069,063 | $-464,675 |
| Stockholders Equity | $-1,462,610 | $-1,405,657 | $-1,069,063 | $-464,675 |
| Other Equity Interest | $-150,000 | - | - | - |
| Retained Earnings | $-15,430,022 | $-11,109,195 | $-9,018,306 | $-5,104,316 |
| Other | ||||
| Ordinary Shares Number | $18,522,295 | $17,635,478 | $17,272,116 | $14,282,314 |
| Share Issued | $18,522,295 | $17,635,478 | $17,272,116 | $14,282,314 |
| Tangible Book Value | $-1,462,610 | $-1,405,657 | $-1,069,063 | $-464,675 |
| Invested Capital | $-1,413,610 | $-1,356,657 | $-1,020,063 | $-391,675 |
| Working Capital | $-1,464,952 | $-1,405,813 | $-1,069,319 | $-464,675 |
| Capital Lease Obligations | $7,532 | $0 | - | - |
| Total Capitalization | $-1,462,610 | $-1,405,657 | $-1,069,063 | $-464,675 |
| Additional Paid In Capital | $14,115,560 | $9,701,774 | $7,947,460 | $4,638,218 |
| Capital Stock | $1,852 | $1,764 | $1,783 | $1,423 |
| Common Stock | $1,852 | $1,764 | $1,783 | $1,423 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $6,544 | $0 | - | - |
| Current Capital Lease Obligation | $988 | $0 | - | - |
| Current Accrued Expenses | $15,439 | $11,599 | $7,759 | $2,619 |
| Dueto Related Parties Current | $483,502 | $460,294 | $537,118 | $142,721 |
| Net PPE | $6,891 | $156 | $256 | $0 |
| Accumulated Depreciation | $-251 | $-151 | $-51 | $0 |
| Gross PPE | $7,142 | $307 | $307 | $0 |
| Other Properties | $307 | $307 | $307 | - |
| Buildings And Improvements | $6,835 | $0 | - | - |
| Properties | $0 | $0 | - | - |
| Treasury Shares Number | - | $0 | - | - |
| Duefrom Related Parties Current | - | - | - | $0 |
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-741,936 | $-451,661 | $-199,287 | $-1,166,971 |
| Operating Activities | ||||
| Operating Cash Flow | $-741,936 | $-451,661 | $-199,287 | $-1,166,971 |
| Cash Flow From Continuing Operating Activities | $-741,936 | $-451,661 | $-199,287 | $-1,166,971 |
| Investing Activities | ||||
| Investing Cash Flow | - | $0 | $-307 | $0 |
| Capital Expenditure | - | - | $-307 | - |
| Cash Flow From Continuing Investing Activities | - | - | $-307 | $0 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $503,088 | $0 | $60,500 | $1,083,199 |
| Financing Cash Flow | $747,996 | $451,623 | $194,685 | $1,169,699 |
| Cash Flow From Continuing Financing Activities | $747,996 | $451,623 | $194,685 | $1,169,699 |
| Net Other Financing Charges | $34,908 | $451,623 | $109,185 | - |
| Net Common Stock Issuance | $503,088 | $0 | $60,500 | $1,083,199 |
| Common Stock Issuance | $503,088 | $0 | $60,500 | $1,083,199 |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $0 | $0 | - |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | - |
| End Cash Position | $6,060 | $0 | $38 | $4,947 |
| Beginning Cash Position | $0 | $38 | $4,947 | $2,219 |
| Changes In Cash | $6,060 | $-38 | $-4,909 | $2,728 |
| Proceeds From Stock Option Exercised | $210,000 | $0 | $25,000 | $13,500 |
| Change In Working Capital | $188,851 | $413,280 | $230,338 | $156,257 |
| Change In Other Working Capital | $-1,995 | - | - | $43,787 |
| Change In Other Current Liabilities | $-157 | $0 | - | - |
| Change In Payables And Accrued Expense | $191,003 | $413,280 | $230,338 | $112,470 |
| Change In Accrued Expense | $3,840 | $3,840 | $5,140 | $2,619 |
| Change In Interest Payable | $3,840 | $3,840 | $5,140 | $2,619 |
| Change In Payable | $187,163 | $409,440 | $225,198 | $109,851 |
| Change In Account Payable | $187,163 | $409,440 | $225,198 | $109,851 |
| Other Non Cash Items | $779,300 | $561,640 | $3,225,014 | $548,148 |
| Stock Based Compensation | $2,609,786 | $664,208 | $259,300 | $307,918 |
| Depreciation Amortization Depletion | $954 | $100 | $51 | $0 |
| Depreciation And Amortization | $954 | $100 | $51 | $0 |
| Depreciation | $954 | $100 | $51 | $0 |
| Net Income From Continuing Operations | $-4,320,827 | $-2,090,889 | $-3,913,990 | $-2,179,294 |
| Issuance Of Debt | - | - | $0 | $73,000 |
| Net Issuance Payments Of Debt | - | - | $0 | $73,000 |
| Net Short Term Debt Issuance | - | - | $0 | $73,000 |
| Short Term Debt Issuance | - | - | $0 | $73,000 |
| Net PPE Purchase And Sale | - | - | $-307 | $0 |
| Purchase Of PPE | - | - | $-307 | $0 |
| Net Long Term Debt Issuance | - | - | - | $73,000 |
| Long Term Debt Issuance | - | - | - | $73,000 |